Papillomavirus vaccine coverage and its determinants in South-Eastern France

Medecine et Maladies Infectieuses

Volumn 43, Issue 5, 2013, Pages 195-201

  Lions, C ^a,b,c   Pulcini, C ^a,d,e   Verger, P ^a,b,c  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Cervical cancer; HPV vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; AGE DETERMINATION; ARTICLE; DESCRIPTIVE RESEARCH; FEMALE; FRANCE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; HUMAN EXPERIMENT; LONGITUDINAL STUDY; NORMAL HUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; REIMBURSEMENT; RURAL AREA; SOCIAL STATUS; SOCIAL WELFARE; VACCINATION;

ADOLESCENT; AGE FACTORS; FEMALE; FRANCE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INSURANCE, HEALTH, REIMBURSEMENT; PAPILLOMAVIRUS VACCINES; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; REFERRAL AND CONSULTATION; RURAL POPULATION; SOCIAL WELFARE; SOCIOECONOMIC FACTORS; URBAN POPULATION; VACCINATION;

EID: 84878786334     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2013.03.003     Document Type: Article

References (30)

1. De Vuyst H., Clifford G., Li N., Franceschi S. HPV infection in Europe. Eur J Cancer 2009, 45(15):2632-2639.
2. Detournay B., Granados-Canal D., El-Hasnaouil A. Assessing the incidence of papillomavirus infections in France. Gynecol Obstet Fertil 2009, 37(2):125-130.
3. Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 2005, 32(Suppl. 1):S16-S24.
4. Rambout L., Hopkins L., Hutton B., Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007, 177(5):469-479.
5. Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374(9706):1975-1985.
6. Insitut de Veille Sanitaire Le Calendrier des vaccinations et les recommandations vaccinales 2012 selon l'avis du Haut Conseil de la santé publique. Bull Epidemiol Hebd 2012, 14-15:161-188.
7. Fagot J.P., Boutrelle A., Ricordeau P., Weill A., Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011, 29(19):3610-3616.
8. Kessels S.J., Marshall H.S., Watson M., Braunack-Mayer A.J., Reuzel R., Tooher R.L. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 2012, 30(24):3546-3556.
9. Dorleans F., Giambi C., Dematte L., Cotter S., Stefanoff P., Mereckiene J., et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010, 15(47).
10. Rouzier R., Giordanella J.P. Coverage and compliance of Human Papilloma Virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. J Adolesc Health 2010, 47(3):237-241.
11. Beltzer N., Lagarde M., Wu-Zhou X., Vongmany N., Gremy I. Les connaissances, attitudes, croyances et comportements face au VIH/Sida en France. Évolutions 1992-1994-1998-2001-2004. Étude ANRS-EN15-KABP 2004, Paris. Observatoire régional de la santé d'Île-de-France, Institut national de prévention et d'éducation pour la santé 2005, Agence nationale de recherches sur le sida.
12. Crochard A., Luyts D., di Nicola S., Goncalves M.A. Self-reported sexual debut and behavior in young adults aged 18-24 years in seven European countries: implications for HPV vaccination programs. Gynecol Oncol 2009, 115(Suppl. 3):S7-S14.
13. Schiller J.T., Castellsague X., Villa L.L., Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl. 10):K53-K61.
14. Dorell C.G., Yankey D., Santibanez T.A., Markowitz L.E. Human papillomavirus vaccination series initiation and completion, 2008-2009. Pediatrics 2011, 128(5):830-839.
15. Davis K., Dickman E.D., Ferris D., Dias J.K. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis 2004, 8(3):188-194.
16. Teitelman A.M., Stringer M., Averbuch T., Witkoski A. Human papillomavirus, current vaccines, and cervical cancer prevention. J Obstet Gynecol Neonatal Nurs 2009, 38(1):69-80.
17. Zimet G.D. Understanding and overcoming barriers to human papillomavirus vaccine acceptance. Curr Opin Obstet Gynecol 2006, 18(Suppl. 1):s23-s28.
18. Monk B.J., Wiley D.J. Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America?. Obstet Gynecol 2006, 108(2):420-424.
19. Nicoletti A., Cervical cancer vaccine. J Pediatr Adolesc Gynecol 2006, 19(6):423-424.
20. Rondy M., van Lier A., van de Kassteele J., Rust L., de Melker H. Determinants for HPV vaccine uptake in the Netherlands: A multilevel study. Vaccine 2010, 28(9):2070-2075.
21. Donadiki E.M., Jimenez-Garcia R., Hernandez-Barrera V., Carrasco-Garrido P., Lopez de Andres A., Velonakis E.G. Human papillomavirus vaccination coverage among Greek higher education female students and predictors of vaccine uptake. Vaccine 2012, 30(49):6967-6970.
22. Koulova A., Tsui J., Irwin K., Van Damme P., Biellik R., Aguado M.T. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008, 26(51):6529-6541.
23. National State, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2008. MMWR 2009, 58:997-1001. Centers for Disease Control and Prevention.
24. Kahn J.A., Lan D., Kahn R.S. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol 2007, 110(1):87-95.
25. Clegg L.X., Reichman M.E., Miller B.A., Hankey B.F., Singh G.K., Lin Y.D., et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control 2009, 20(4):417-435.
26. Downs L.S., Smith J.S., Scarinci I., Flowers L., Parham G. The disparity of cervical cancer in diverse populations. Gynecol Oncol 2008, 109(Suppl. 2):S22-S30.
27. Freeman H.P., Wingrove B.K. Excess cervical cancer mortality: a marker for low access to health care in poor communities. Rockville: md: national cancer institute 2005, MD: National Cancer Institute, Center to Reduce Cancer Health disparities, Rockville, Report No.: NIH Pub. No. 05-5282.
28. Garner E.I. Cervical cancer: disparities in screening, treatment, and survival. Cancer Epidemiol Biomarkers Prev 2003, 12(3):242s-s247.
29. Yin D., Morris C., Allen M., Cress R., Bates J., Liu L. Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups?. Cancer Causes Control 2010, 21(10):1721-1730.
30. Crosby R.A., Casey B.R., Vanderpool R., Collins T., Moore G.R. Uptake of free HPV vaccination among young women: a comparison of rural versus urban rates. J Rural Health 2011, 27(4):380-384.